Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4% - Here's Why

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shot up 4% during mid-day trading on Wednesday . The stock traded as high as $5.77 and last traded at $5.67. 13,271,401 shares traded hands during trading, a decline of 9% from the average session volume of 14,645,055 shares. The stock had previously closed at $5.45.

Analyst Ratings Changes

RXRX has been the topic of several analyst reports. Needham & Company LLC reduced their price objective on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Morgan Stanley reduced their price target on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Leerink Partners lowered their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Finally, Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $7.60.

Recursion Pharmaceuticals Trading Down 4.3%

The firm has a 50-day moving average of $4.85 and a 200 day moving average of $6.34. The company has a market cap of $2.10 billion, a P/E ratio of -3.38 and a beta of 0.84. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The business had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals's quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.39) earnings per share. On average, analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of large investors have recently bought and sold shares of RXRX. Private Trust Co. NA bought a new position in Recursion Pharmaceuticals in the fourth quarter worth approximately $27,000. AlphaQuest LLC bought a new position in shares of Recursion Pharmaceuticals in the 1st quarter worth $36,000. GAMMA Investing LLC grew its position in Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after purchasing an additional 2,026 shares during the period. Farther Finance Advisors LLC increased its stake in Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after purchasing an additional 1,353 shares in the last quarter. Finally, NewEdge Advisors LLC increased its stake in Recursion Pharmaceuticals by 43.7% during the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after purchasing an additional 2,387 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.